Clinical Trial Update: PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update of PS-341 (bortezomib) in patients with advanced solid tumors or lymphoma. The study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Small Intestine Cancer

Drugs mentioned

• PS-341 (bortezomib)

Snippet

Sponsor: NYU Langone Health | Conditions: Lymphoma, Small Intestine Cancer | Phase 1 | Status: COMPLETED